Company intelligence / Profile preview

Complix

Ownership: Private
Development stage: Preclinical

Overview

Pre-clinical proof of concept data has demonstrated that CPABs engage specifically with targets and cause therapeutic effects in animal models of cancer and autoimmune disease[1]

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Cell Penetrating Alphabodies (CPABs)Alphabodies
Industry: Biotech

Drug pipeline

4 assets

Cell Penetrating Alphabodies targeting COVID-19

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

The company has multiple product candidates being developed in collaboration with partners (specific partners not named)[2]

Beyond the preview

Go deeper on Complix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complix.

Explore the full profile